Roivant announces positive results for batoclimab myasthenia gravis (mg) and chronic inflammatory demyelinating polyneuropathy (cidp) studies

New york, march 19, 2025 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its phase 3 study of batoclimab in mg and initial results from period 1 of its phase 2b study in cidp.
MG Ratings Summary
MG Quant Ranking